Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.

Hozzl · 2023-12-15T15:51:38Z

Explore the details of House Bill 309 Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care. currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/15/2023, 3:51 PM

Summary of Bill HRES 309

Bill 118 HRES 309, titled "Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care," is a resolution that was introduced in the US Congress. The purpose of this resolution is to affirm the belief that the Food and Drug Administration (FDA) has the authority to approve drugs that are used for abortion care.

The resolution emphasizes the importance of ensuring that the FDA is able to fulfill its regulatory responsibilities in a timely and efficient manner, particularly when it comes to approving drugs that are used for abortion care. It also highlights the need for the FDA to base its decisions on scientific evidence and medical expertise, rather than political considerations.

The resolution does not seek to change any existing laws or regulations related to abortion care. Instead, it simply expresses the opinion of the House of Representatives that the FDA should be able to carry out its duties without interference or obstruction. Overall, Bill 118 HRES 309 is a non-binding resolution that serves to reaffirm the belief that the FDA has the authority to approve drugs for abortion care. It is a statement of support for the FDA's regulatory role in ensuring the safety and efficacy of medications used in abortion procedures.

Congressional Summary of HRES 309

This resolution expresses the sense of the House of Representatives that the Food and Drug Administration (FDA) has the authority to review and approve drugs pursuant to its own expertise, and that recent court decisions blocking the FDA's approval of mifepristone (which is used in medication abortion) violate congressional intent with respect to the FDA's authority.

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill HRES 309

Bill HRES 309 is currently in the status of Bill Introduced since April 19, 2023. Bill HRES 309 was introduced during Congress 118 and was introduced to the House on April 19, 2023. Bill HRES 309's most recent activity was Referred to the House Committee on Energy and Commerce. as of April 19, 2023

Bipartisan Support of Bill HRES 309

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill HRES 309

Primary Policy Focus

Health

Alternate Title(s) of Bill HRES 309

Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.Expressing the sense of the House of Representatives that the Food and Drug Administration has the authority to approve drugs for abortion care.

Start holding our government accountable!